Participating Companies


Adrenomed AG
Car­dio­vas­cu­lar and Sep­sis, Adre­cizumab Ph 2, bio­mark­er-guid­ed, mon­o­clo­n­al anti­body for sep­tic shock; to­p­li­nee da­ta re­leased late Feb. Adre­cizumab showed low­er all-cause mor­tal­i­ty for treat­ed pts com­pared to place­bo (28% mor­tal­i­ty rate in 28-day fol­low-up). De­tailed da­ta com­ing in fol­low­ing few months. [more in­for­ma­tion]
Affimed N.V. [AFMD] US$349 MM MCap
NK cell en­gager AFM13 (CD30/CD16A) to en­ter a Phase 2 reg­is­tra­tion study in CD30-pos­i­tive pe­ripher­al T cell lym­pho­ma and an in­vesti­ga­tor-spon­sored study by MDACC of AFM13 com­bined with al­lo­gene­ic NK cells in re­lapsed/re­frac­to­ry CD30-pos­i­tive lym­pho­ma. [more in­for­ma­tion]
AM-Pharma B.V.
Treat­ing sep­sis as­so­ci­at­ed acute kid­ney in­jury (AKI) with pro­pri­e­tary re­com­bi­nant al­ka­line phos­pha­tase (re­cAP). Re­sults from Ph 2 trial in 300+ pts, de­mon­s­trat­ed rel­a­tive im­prove­ment of 40%+ OS in re­cAP group. Ini­ti­at­ing Ph 3 in Q3 2020 – in­ter­im look (n=400) exp Q3 2021 (P end­point: Day 28 all-cause mor­tal­i­ty). [more in­for­ma­tion]
Antev
Phase 3 ready, Tevere­lix, a long act­ing in­jectable pep­tide GnRH an­ta­g­on­ist. Lead in­di­ca­tion for pros­tate can­cer, fol­lowed by be­nign pro­stat­ic hy­per­pla­sia (BPH), acute uri­nary re­ten­tion (AUR), uterine fi­broids and en­dometrio­sis. Over 450 sub­jects have been dosed over 850 times to date with no se­ri­ous ad­verse re­ac­tions and good lo­cal tol­er­ance. [more in­for­ma­tion]
Apexigen
CD40 ag­on­ist mAb; 170+ pts dosed (mono & com­bi sett­ings). 7 on­go­ing Ph 2s, undis­closed oc­u­lar dis­ease pro­gram in Ph 3. AACR: Ph 1b da­ta (w/Park­er Inst); col­labs w/BMY, MDACC, Yale, et al [more in­for­ma­tion]
Aptorum Group [APM] US$105 MM MCap
Ap­to­rum is Hong Kong based, US list­ed com­pany (Mcap $100m) fo­cused on gen­er­at­ing late stage clin­i­cal can­di­dates by de­vel­op­ing al­ready ap­proved drugs for new or­phan in­di­ca­tions, as well as in­fec­tious dis­eas­es. Pipe­line – • SACT-1 for Neu­roblas­to­ma – ph2/3 trial planned for 2H’20 • SACT-COV­19 – COVID-19 treat­ment - pre­clin­i­cal [more in­for­ma­tion]
Ascentage Pharma [6855.HK]
As­cen­t­age Phar­ma has built a pipe­line of eight clin­i­cal drug can­di­dates, in­clud­ing a nov­el, high­ly po­tent Bcl-2/Bcl-xL in­hibi­tor, as well as can­di­dates aimed at IAP and MD­M2-p53 path­ways, and next-gen­er­a­tion ty­ro­sine ki­nase in­hibi­tors. The com­pany has been con­duct­ing 28 Phase I/II clin­i­cal trials to eval­u­ate the eight drug can­di­dates in the Unit­ed States, Aus­tralia, and Chi­na. [more in­for­ma­tion]
BerGenBio [BGBIO:OS] NKr3,469 MM MCap
De­vel­op­ing first-in-class se­lec­tive Axl ki­nase in­hibi­tors for liquid and solid can­cers, lead can­di­date is bem­cen­tinib (BG­B324) in four com­pany-spon­sored trials. [more in­for­ma­tion]
BioXcel Therapeutics, Inc. [BTAI] US$1,080 MM MCap
BX­CL501 (sublin­gual dexmede­to­mi­dine): Phase 3 trials on­go­ing for the acute treat­ment of ag­i­ta­tion in pa­tients with schi­zophre­nia (SERENI­TY I) and bipo­lar di­s­or­der (SERENI­TY II). Phase 1b/2 trial (TRAN­QUIL­I­TY) on­go­ing for the acute treat­ment of ag­i­ta­tion as­so­ci­at­ed with ge­ri­a­tric de­men­tia. [more in­for­ma­tion]
Camallergy
Ca­mal­ler­gy de­vel­ops and pro­vides new treat­ments for com­mon food al­ler­gies. [more in­for­ma­tion]
CASI Pharmaceuticals Inc. [CASI] US$242 MM MCap
Launched EVOMELA® (mel­pha­lan for in­jec­tion, mul­ti­ple myelo­ma) in Au­gust 2019, on­ly mel­pha­lan com­mer­cial­ly avai­l­able in Chi­na; ad­vanc­ing de­vel­op­ment of an­ti-CD19 T-cell ther­a­py (CNC­T19) in B-NHL and B-ALL and an­ti-CD38 mAb (CID-103) in mul­ti­ple myelo­ma, fo­cused on be­com­ing Chi­na’s ma­jor he­ma­tol­o­gy on­col­o­gy com­pany; [more in­for­ma­tion]
Catabasis Pharmaceuticals Inc [CATB] US$120 MM MCap
Rare dis­ease pipe­line, with lead prod­uct Edasa­lonex­ent in Ph 3 trial in Duchenne mus­cu­lar dys­tro­phy re­gard­less of mu­ta­tion type. North Star Am­bu­la­to­ry As­sess­ment as the pri­mary end­point based on Phase 2 re­sults and FDA in­put. Top-line re­sults ex­pect­ed in 2020. [more in­for­ma­tion]
CerSci Therapeutics
De­vel­op­ing a new gen­er­a­tion of non-opi­oid medicines to treat acute post-op­er­a­tive and chron­ic neu­ro­path­ic pain. Lead pro­gram in Phase 1 (MAD/SAD/Food Ef­fect), CT-044, tar­get­ing re­ac­tive spe­cies that cause neu­ro­n­al ion chan­nel hy­per-sen­si­ti­za­tion, known to trig­ger pain. [more in­for­ma­tion]
Engage Therapeutics
En­gage Ther­a­peu­tics is fo­cused on bring­ing pa­tients with epilep­sy suf­fer­ing from un­con­trolled seizures what could be the first res­cue treat­ment with the po­ten­tial to stop their seizures. One in three of those peo­ple have what is con­sid­ered re­frac­to­ry epilep­sy with un­con­trolled seizures, as one or more an­ti-epilep­tic drugs has not worked for them. [more in­for­ma­tion]
ESSA Pharma Inc. [EPIX] US$129 MM MCap
1Q20 IND sub­mis­sion for lead as­set, EPI-7386, a small molecule tar­get­ing n-ter­mi­nal do­main of an­dro­gen re­cep­tor for mCR­PC. First pa­tient dosed in EPI-7386 Phase 1 study in mCR­PC pa­tients fail­ing se­cond gen­er­a­tion an­tian­dro­gens by 2Q20. [more in­for­ma­tion]
Evofem Biosciences, Inc. [EVFM] US$260 MM MCap
Evofem Bio­s­ciences (EVFM) is de­vel­op­ing Am­pho­ra®, a Mul­ti­pur­pose Vag­i­nal pH Reg­u­la­tor (MVP-R) and non-hor­mo­n­al, on-de­mand, wo­m­an-con­trolled vag­i­nal gel for birth con­trol and the pre­ven­tion of uro­geni­tal ac­qui­si­tion of cer­tain STIs. PD­U­FA for con­tra­cep­tion of May 25, 2020. Phase 3 for ch­lamy­dia and gon­or­rhea ex­pect­ed to ini­ti­ate in 2020. [more in­for­ma­tion]
Faraday Pharmaceuticals
El­e­men­tal re­duc­ing agents for crit­i­cal care treat­ment to pre­vent car­di­ac and skele­tal mus­cle loss: lead can­di­date FDY-5301 Ph 3 (piv­o­tal) to ini­ti­ate mid-2020 for reper­fu­sion in­jury fol­low­ing heart at­tack (AMI); da­ta ear­ly 2023. SPA sub­mis­sion re­ceived by FDA Jan 22, 2020 and ini­tial feed­back re­ceived Feb 2020 - Type A meet­ing re­quest, like­ly in April 2020. Sig­ni­f­i­cant ad­di­tio­n­al treat­ment ap­pli­ca­tions with limit­ed to no com­pe­ti­tion. $57M raised to date from Arch Ven­ture Part­n­ers, Po­laris Part­n­ers, WRF, Osa [more in­for­ma­tion]
Forbius
Se­lec­tive in­hibi­tors of TGF Be­ta & EGFR path­ways. AACR: (+) Ph 1 da­ta. 3 on­go­ing Ph 2 trials (SCCHN, NS­CLC, TN­BC); ad­dl Ph 1 trials in IO, Sys­temic Scle­ro­sis & Myelo­fi­bro­sis [more in­for­ma­tion]
HaemaLogiX
Pro­pri­e­tary, dif­fer­en­ti­at­ed B cell tar­gets en­gaged via anti­body and CAR-T pro­grams Kap­paMab & Lamb­daMab tar­get ac­ti­vat­ed plas­ma cell anti­gens (KMA/LMA); Kap­paMab plus RevDex vs. RevDex Ph 2b in MM, da­ta 1H20; Kap­pa CAR-T Ph 1 Q120 in MM; Ca­pac­i­ty for du­al-tar­get­ing via CD-19, BC­MA, etc; Lamb­daMab in pre­clin­i­cal for amy­loi­do­sis [more in­for­ma­tion]
I-Mab Biopharma [IMAB] US$1,696 MM MCap
I-Mab Bio­phar­ma is a Chi­na based bio­phar­ma­ceu­ti­cal with fo­cus on de­vel­op­ing in­no­va­tive bi­o­log­ics in the ar­eas of im­muno-on­col­o­gy and au­toim­mune dis­ease for the glob­al mar­kets, in­clud­ing Chi­na; [more in­for­ma­tion]
Impact Therapeutics Inc
Based in Chi­na, IM­PACT is com­mitt­ed to the dis­cov­ery and de­vel­op­ment of best-in-class ther­a­peu­tics to treat can­cer and other life-threat­en­ing dis­eas­es. IM­PACT is a clin­i­cal-stage com­pany with a unique small-molecule drug dis­cov­ery and de­vel­op­ment plat­form tar­get­ing DDR. IM­PACT's lead­ing pro­gram, PARP in­hibi­tor IM­P4297, is cur­rent­ly un­der­go­ing phase I trials in Aus­tralia and Chi­na. [more in­for­ma­tion]
Incysus Therapeutics
The com­pany's ser­vices fo­cus on uti­l­iz­ing ge­net­i­cal­ly mod­i­fied gam­ma-del­ta T cells across a Drug Re­sis­tance Im­munother­a­py (DRI) plat­form that ad­dress­es the chal­lenges faced while tar­get­ing cold, low mu­ta­tion can­cers, en­abling the tar­get­ing of ma­lig­nant cells and po­ten­tial­ly more ef­fec­tive treat­ments for pa­tients with dif­fi­cult-to-treat solid tu­mor can­cers. [more in­for­ma­tion]
Junshi Biosciences [1877:HK]
Fo­cused on de­vel­op­ing ther­a­pies in I-O, au­toim­mune and metabolic dis­eas­es. 13 pipe­line can­di­dates (7 in I-O, 2 in metabolic, 3 in au­toim­mune and 1 in neu­ro­log­i­cal dis­eas­es). JS001, or tori­pal­imab, is ap­proved by the NM­PA and the first mar­ket­ed an­ti-PD-1 mAb anti­body self-de­vel­oped by a PRC com­pany. For full year 2019, tori­pal­imab sales were ap­prox­i­mate­ly $11.1M / 135,525 bot­tles. [more in­for­ma­tion]
Kineta Inc.
Kine­ta (Pri­vate) - whol­ly owned pre­clin­i­cal an­ti-VIS­TA (in­nate im­mune tar­get) anti­body re­pro­grams the tu­mor mi­croen­vi­ron­ment and is dif­fer­en­ti­at­ed from other im­munother­a­pies by block­ing sup­pres­sive cells in cold tu­mors. $520M deal with Pfiz­er for its small molecule RIG-I im­munother­a­py and $360M+ deal with Ge­nen­tech for KCP506, pre­clin­i­cal, non-opi­oid for chron­ic pain. [more in­for­ma­tion]
Landos Biopharma
Based on ex­ten­sive pre­clin­i­cal studies, Lan­dos has vali­dat­ed a unique mech­anism of ac­tion in­volv­ing LAN­CL2 that ex­erts po­tent an­ti-in­flam­ma­to­ry ef­fects with an out­s­tand­ing safe­ty pro­file. Lead as­set BT-11 Phase 2 in­ter­im read out in mid-2020 in UC. [more in­for­ma­tion]
Lineage Cell Therapeutics [LCTX] US$118 MM MCap
Cell ther­a­py com­pany with 3 cl­ni­cal pro­grams 1) OpRe­gen, an RPE tran­s­plant ther­a­py in Ph1/2a de­vel­op­ment for the treat­ment of dry-AMD. 2) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py for acute spi­nal cord in­juries with Or­phan and RMAT desig­na­tions. 3) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in a Ph 1 for NS­CLC con­duct­ed by CRUK. [more in­for­ma­tion]
Maxcyte [MXCT:LN] £156 MM MCap
Har­ness­ing cell-en­gi­neer­ing de­liv­ery plat­form to de­vel­op small molecules, vaccines, and cell and gene ther­a­pies. Plat­form based on Flow Elec­tro­po­ra­tion™ Tech­nol­o­gy, with abil­i­ty to trans­fect pri­mary cells, stem cells and cell lines with min­i­mal cell dis­tur­bance and trans­fec­tion ef­fi­cien­cies routine­ly >90% for a va­ri­e­ty of cell types. [more in­for­ma­tion]
NervGen Pharma [NGENF] US$51 MM MCap
Nerv­Gen Phar­ma is a de­vel­op­ing nov­el ther­a­peu­tics for pa­tients suf­fer­ing from med­i­cal con­di­tions re­lat­ed to nerve da­m­age sus­tained as a re­sult of (i) in­jury, such as in spi­nal cord in­jury, or (ii) neu­rode­gen­er­a­tive dis­ease, such as MS or Alzheimer's dis­ease. [more in­for­ma­tion]
NeuroRx
De­vel­op­ing the first Glx tar­get­ed an­tide­pres­sant to ad­dress sui­ci­dal­i­ty in bipo­lar de­pres­sion. Lead can­di­date, NRX-101 is in Phase 2b/3 de­vel­op­ment, ini­ti­at­ed in Ju­ly 2019 (Break­through, SPA and Fast Track by FDA) for Se­vere Bipo­lar De­pres­sion in pts w Acute Sui­ci­dal Idea­tion and Be­havior. Re­port­ed Phase 2 ef­fi­ca­cy and safe­ty da­ta for NRX-011 in De­cem­ber 2018. [more in­for­ma­tion]
NexImmune, Inc.
Mul­ti-anti­gen-spe­cif­ic T cell ther­a­py. Syn­thet­ic nano­par­ti­cles de­c­o­rat­ed w a com­bo of mul­ti­ple tu­mor rel­e­vant anti­gens and co-sti­m­u­la­to­ry sig­nals en­gag­ing di­rect­ly w tar­get­ed T cells. Two Ph 1's on­go­ing. [more in­for­ma­tion]
NorthSea Therapeutics
First-in class, oral, struc­tu­ral­ly en­gi­neered fat­ty acids [SE­FAs] ad­dress­ing NASH and as­so­ci­at­ed metabolic di­s­or­ders via unique tar­get­ing of path­ways reg­u­lat­ing metabolism, oxida­tive stress, in­flam­ma­tion, and fi­bro­sis. $40m Se­ries B (Jan 2020) with ven­Bio Part­n­ers (lead) and Sofin­no­va In­vest­ments. [more in­for­ma­tion]
OnKure Therapeutics, Inc.
De­vel­op­ing epi­ge­net­ic can­cer ther­a­pies in­clud­ing HDAC in­hibi­tors. Lead as­set OKI-179 is a class 1 HDAC in­hibi­tor in Ph 1. [more in­for­ma­tion]
PAION AG [PAIOF] US$212 MM MCap
Remi­ma­zo­lam: short-act­ing anes­thet­ic. Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US ap­pro­val filed by part­n­er Cos­mo Phar­ma­ceu­ti­cals in June 2019. Ini­ti­at­ed Ph 3 in gen­er­al anes­th­e­sia in EU in Ju­ly 2018, exp com­ple­tion 2020. [more in­for­ma­tion]
Paradigm BioPharma [PBIGF] US$537 MM MCap
Launch­ing Ph 3 in 2020 in OA pts w/bone mar­row ede­ma le­sions (BML). Pos­i­tive Ph2b re­sults in sub­jects w/OA & BML - stat sig im­prove­ment on pain re­duc­tion & BML vol­ume/grade re­duc­tions on MRI. Q12020: ini­tial da­ta from com­pas­sio­nate use trial (ex-NFL sub­jects w/OA) and joint IND sub­mis­sion to FDA/EMA for piv­o­tal trial in Mu­copolysacchari­do­sis. Exp AUS rev-gen in Q3 20. [more in­for­ma­tion]
PharmaMar SA [PHM:ES]
Yon­delis (soft tis­sue sar­co­ma and ovarian can­cer) com­mer­cial­ized with di­rect sales-force in EU and part­n­er­ship in US with Janssen. Signed li­cens­ing agree­ment with Jazz Phar­ma for Lur­binecte­din in the US - up­front pay­ment of $200M, $100mm on ap­pro­va­land up to $550M sales mile­s­tones. Jazz to launch Zepzel­ca in US Ju­ly 2020. [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €735 MM MCap
RU­CON­EST (rhC1INH), the on­ly re­com­bi­nant en­zyme re­place­ment ther­a­py mar­ket­ed for acute Hered­i­tary An­gioede­ma (HAE) at­tacks and be­ing de­vel­oped for large un­met in­di­ca­tions. [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] US$160 MM MCap
An­ti­calins (en­gi­neered lipo­calin pro­teins) for re­sp & on­co dis­eas­es. Im­mi­nent da­ta for AZN-part­nered PRS-060 in­haled IL4 for mod-to-se­vere asth­ma. Cash of $128MM in the bank as of March 2019. [more in­for­ma­tion]
Ryvu Therapeutics [RVU:WAR]
Po­ten­tial first in class CD­K8 in­hibi­tor for leukemias, lym­pho­mas, and solid tu­mors in Ph1b in AML and high-risk MDS, PIM/FLT3 ki­nase in­hibi­tor in Ph 1/2 in AML (part­nered w Me­nari­ni). Da­ta in 2020. Ear­ly stage pipe­line ad­dress­ing emerg­ing solid tu­mor tar­gets. [more in­for­ma­tion]
Sol-Gel Technologies Ltd. [SLGL] US$192 MM MCap
Com­mer­cial­iz­ing brand­ed gener­ic top­i­cal drug prod­ucts (skin dis­eas­es). Two pos­i­tive Phase 3 pro­grams in rosacea and acne, with NDAs ex­pect­ed in 1H20 and 2H20, re­spec­tive­ly. Ad­di­tio­n­al brand­ed pipe­line as­sets in­clude SGT-210, er­lo­tinib, for the treat­ment of punc­tu­ate pal­mo­plan­tar ker­a­to­der­ma, and pre­clin­i­cal as­set tap­i­narof and rof­lu­mi­last. Sol-Gel al­so has rev­enue from sev­er­al gener­ic col­lab­o­ra­tions. [more in­for­ma­tion]
Targovax [TRVX:OS] NKr510 MM MCap
Pre­lim­i­nary Ph1b da­ta of OV ON­COS-102+che­mo in me­sothe­lio­ma re­sults: com­bo mPFS=8.4 mos. vs. con­trol mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Up­com­ing mile­s­tones: up­dat­ed clin­i­cal & im­mune da­ta in Ph2 me­sothe­lio­ma (1H20); pre­clin­i­cal da­ta on next-gen OV w/ dou­ble trans­genes (1H20); and clin­i­cal da­ta from Ph1 me­lano­ma study, part 2 with ex­tend­ed dos­ing (2H20). [more in­for­ma­tion]
Teon Therapeutics
Pipe­line of next-gen­er­a­tion can­cer ther­a­peu­tics tar­get­ing GPCRs in­clud­ing a high­ly-spe­cif­ic A2B an­ta­g­on­ist and EP4 an­ta­g­on­ist, both slat­ed to en­ter Phase 1b trials in 2021. [more in­for­ma­tion]
Vaccitech Limited
Pro­pri­e­tary ChA­dOx (prime) and MVA (boost) tech­nol­o­gy plat­form in­duces and main­tains CD8+ T-cells at the max­i­mum lev­els pub­lished to date. Ph1/2 for HPV and HBV im­munother­a­pies ini­ti­at­ing 1H20. Two can­cer im­munother­a­py pro­grams (per­so­n­al­ized vaccine and MAGE-NYE­SO ther­a­peu­tics) en­ter clin­ic in 2020. Two ChA­dOx1 vaccines for coro­n­avirus­es with Ox­ford Univ fund­ed by CEPI – COVID-19 (an­nounced 3/10/20) and MERS (Ph.1 com­plete). $150M fund­ing at Jen­n­er In­sti­tute and com­pany raised $48M since for­ma­tion in 2016 [more in­for­ma­tion]
Yiviva
There is a need for new ap­proach­es to treat un­met med­i­cal needs, and there is an op­por­tu­ni­ty for in­no­va­tion be­cause: Our bodies are in­ter-con­nect­ed sys­tems. Con­ven­tio­n­al West­ern medicine us­ing a sin­gle chem­i­cal en­ti­ty to tar­get a sin­gle tar­get are of­ten in­suf­fi­cient – with limit­ed ef­fi­ca­cy and se­ri­ous side ef­fects for pa­tients. [more in­for­ma­tion]